Litcius/Paper detail

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, Antje Blank, Н. В. Воронкова, Tatiana Stepanova, Olga Sagalova, Vladimir Chulanov, М. Ф. Осипенко, Viacheslav Morozov, Natalia Geyvandova, S.S. Sleptsovа, И. Г. Бакулин, И. М. Хаертынова, Marina Rusanova, Anita Pathil, Uta Merle, Birgit Bremer, Lena Allweiss, Florian A. Lempp, Kerstin Port, Mathias Haag, Matthias Schwab, Julian Schulze zur Wiesch, Markus Cornberg, Walter E. Haefeli, Maura Dandri, A. A. Alexandrov, Stephan Urban

2022The Lancet Infectious Diseases158 citationsDOI

Topics & Concepts

MedicineInternal medicineHepatitis B virusPopulationHepatitis BHepatitis C virusHepatitis D virusClinical endpointRandomized controlled trialGastroenterologyVirusImmunologyHBsAgEnvironmental healthHepatitis B Virus StudiesHepatitis C virus researchHepatitis Viruses Studies and Epidemiology
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial | Litcius